Saturday, October 18, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > News > Landmark trial shows potential for psychedelic drugs to treat mental illness

Landmark trial shows potential for psychedelic drugs to treat mental illness

in News
- Landmark trial shows potential for psychedelic drugs to treat mental illness
Share on LinkedinShare on WhatsApp

New results from a clinical trial using MDMA to treat post-traumatic stress disorder showed the promise of a stigmatized drug to treat mental illness.

Drugs such as psilocybin and MDMA are rising in profile as mental illness treatment options after results from a phase 3 trial of MDMA combined with talk therapy for post-traumatic stress disorder showed impressive results, according to researchers.

“This is a pivotal event,” said Elemer Piros, a biotech analyst at Roth Capital Partners who covers the emerging alternative mental health treatment space. “It may not seem humongous, but it is one of the best and most rigorously executed trials in the space.”

The results of the MDMA study, whose senior author is Rick Doblin, founder and executive director of the Multidisciplinary Association for Psychedelic Studies, are expected to be published in the journal Nature Medicine on Monday and FDA approval could come by 2023, according to The New York Times.

A recent Imperial College London study of psilocybin use in depression reported in The New England Journal of Medicine also produced positive results.

In 2019, 51.5 million adults were living with a mental illness in the U.S., and the number of people suffering and drug costs, are projected to grow in the years ahead, with Covid-19 compounding mental health issues globally.

Tags: Mental illnesspsychedelic drugs

Related Posts

US stock exchanges end week up
News

Dow futures drop 300 points as record sell-offs continue

Trump strikes tariff deal with Merck KGaA
News

Trump strikes tariff deal with Merck KGaA

United Airlines CEO Scott Kirby says prolonged U.S. shutdown could harm industry
News

United Airlines CEO Scott Kirby says prolonged U.S. shutdown could harm industry

Salesforce lowers outlook during CFO transition
News

Salesforce posts Q2 win, increases 2030 forecast

Costco begins selling gold bars to customers
News

Gold rises 5% to reach another record high

CEOs of Wells Fargo and Pfizer call on the U.S. to promote innovation
News

CEOs of Wells Fargo and Pfizer call on the U.S. to promote innovation

Stellantis announces $13 billion U.S. investment
News

Stellantis announces $13 billion U.S. investment

Morgan Stanley penalizes employees for WhatsApp breaches
News

Morgan Stanley’s Q3 earnings jump 45%

BlackRock, Nvidia, xAI and Microsoft to acquire Aligned Data Centers
News

BlackRock, Nvidia, xAI and Microsoft to acquire Aligned Data Centers

LendingTree CEO Doug Lebda dies
News

LendingTree CEO Doug Lebda dies

No Result
View All Result

Recent Posts

  • The Legendary Diane Keaton Dies Aged 79
  • Baking Soda Skin Care Hacks: Why Experts Say to Avoid These Viral Trends
  • Bulgaria is Worth Visiting
  • Dow futures drop 300 points as record sell-offs continue
  • Trump strikes tariff deal with Merck KGaA

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.